Suppr超能文献

2020年墨西哥视网膜母细胞瘤面临的挑战:观点与解决方案。

Challenge of Retinoblastoma in Mexico in 2020: Perspectives and Solutions.

作者信息

Garza-Garza Lucas A, Ruiz-Lozano Raúl E, Rebolledo-Méndez Genaro, Ibarra-Nava Ismael, Morales-Garza Héctor J, Ancona-Lezama David

机构信息

Tecnologico de Monterrey, School of Medicine and Health Sciences, Ocular Oncology Service at Institute of Ophthalmology and Visual Sciences, Hospital Zambrano-Hellion, San Pedro Garza Garcia, Nuevo León, Mexico.

Writing Lab, TecLabs, Vicerrectoria de Investigación y Transferencia de Tecnología, Tecnologico de Monterrey, Monterrey, Mexico.

出版信息

J Ophthalmol. 2020 Aug 10;2020:1953602. doi: 10.1155/2020/1953602. eCollection 2020.

Abstract

Early diagnosis and positive outcomes of retinoblastoma in childhood have been positively correlated with the economic wealth of high-income countries (HICs) worldwide. Adequate curability and survival rates, adherence to treatment, presence of poor prognostic initial clinical signs, and metastatic disease at diagnosis appear to have a less favorable picture in low-income countries (LICs). However, this is not always the case. An example is Argentina, where disease-free survival rates of retinoblastoma are notably higher than expected when taking into consideration its economic situation. Unfortunately, as in other Latin American LICs, retinoblastoma outcomes in Mexico are worrisome. Interestingly, the Human Development Index (HDI) in Mexico varies widely between its different geographical regions. While in some states, the HDI resembles those of high-income countries, and in others, the opposite is observed. A unifying picture of Mexico's developmental status, health resources, indicators, and other factors possibly influencing outcomes in retinoblastoma is currently unavailable. The present review explores the previously mentioned factors in Mexico and compares them to other countries. Additionally, it recommends solutions or enhancements where possible.

摘要

儿童视网膜母细胞瘤的早期诊断和良好预后与全球高收入国家(HICs)的经济财富呈正相关。在低收入国家(LICs),治愈率和生存率是否足够、对治疗的依从性、诊断时预后不良的初始临床体征的存在以及转移性疾病,情况似乎不太乐观。然而,情况并非总是如此。阿根廷就是一个例子,考虑到其经济状况,视网膜母细胞瘤的无病生存率明显高于预期。不幸的是,与其他拉丁美洲低收入国家一样,墨西哥视网膜母细胞瘤的治疗结果令人担忧。有趣的是,墨西哥的人类发展指数(HDI)在其不同地理区域之间差异很大。在一些州,HDI与高收入国家相似,而在其他州则相反。目前尚无法全面了解墨西哥的发展状况、卫生资源、指标以及其他可能影响视网膜母细胞瘤治疗结果的因素。本综述探讨了墨西哥上述因素,并与其他国家进行了比较。此外,它还在可能的情况下推荐了解决方案或改进措施。

相似文献

10

本文引用的文献

2
Evidence for national universal eye health plans.国家全民眼健康计划的证据。
Bull World Health Organ. 2018 Oct 1;96(10):695-704. doi: 10.2471/BLT.18.213686. Epub 2018 Aug 27.
3
Retinoblastoma in Asia.亚洲的视网膜母细胞瘤。
Eye (Lond). 2019 Jan;33(1):87-96. doi: 10.1038/s41433-018-0244-7. Epub 2018 Nov 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验